Capital IX Sofinnova Form 3 CinCor Pharma / Partners SAS Sofinnova ownership change

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0104
Estimated average burden
hours per response:	0.5

1. Name and Address of Reporting Person^*

Sofinnova Partners SAS

(Last) (First) (Middle)

7-11 BOULEVARD HAUSSMANN

(Street)

PARIS I0 75009

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
01/06/2022

3. Issuer Name and Ticker or Trading Symbol
CinCor Pharma, Inc. [ CINC ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	(1)	Common Stock	2,941,176	(1)	I	By Sofinnova Capital IX(2)
Series B Preferred Stock	(1)	(1)	Common Stock	926,470	(1)	I	By Sofinnova Capital IX(2)

1. Name and Address of Reporting Person^*

Sofinnova Partners SAS

(Last) (First) (Middle)

7-11 BOULEVARD HAUSSMANN

(Street)

PARIS I0 75009

(City) (State) (Zip)

1. Name and Address of Reporting Person^*

Sofinnova Capital IX

(Last) (First) (Middle)

7-11 BOULEVARD HAUSSMANN

(Street)

PARIS I0 75009

(City) (State) (Zip)

Explanation of Responses:

1. Each share of Series A Preferred Stock and Series B Preferred Stock will automatically convert into shares of Common Stock on a 3.4:1 basis immediately prior to the closing of the Issuer's initial public offering and have no expiration date.

2. The shares are directly held by Sofinnova Capital IX ("SC IX"). Sofinnova Partners SAS ("Sofinnova Partners") is the management company of SC IX and may be deemed to share voting and investment power over the shares held by SC IX. Sofinnova Partners disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein.

Remarks:

	Sofinnova Partners SAS, By Monique Saulnier, Managing Partner	01/06/2022
	Sofinnova Capital IX, By: Sofinnova Partners SAS, its management company, By /s/ Monique Saulnier, Managing Partner	01/06/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.